Professor Steven Nissen, Cleveland Clinic, Ohio, USA, discusses HORIZON trial methodology and baseline patient data, and reviews recently reported results from the Lp(a)FRONTIERS APHERESIS trial which investigated the effects of pelacarsen on need for apheresis in patients with hyperlipoproteinemia(a) and established cardiovascular disease.
Please login or create a FREE account to view this content
Educational Partners of the 2nd Closed Scientific Expert Meeting of the Editorial Board
Principal partners:
Guest partners:
